Hapoel Tel Aviv Signs Douglas Aveso in Record Deal with Bayern Munich Medical Support
Hapoel Tel Aviv officially signed Douglas Aveso on August 5, 2026, securing the Ghanaian forward on a four-year contract for a transfer fee of 2.2 million euros paid to Red Star Belgrade. The deal, potentially rising to 2.4 million euros with bonuses, is the largest in the club's history. Part of the payment was offset by waiving a future fee from Red Star related to former player Louizos Louizo.
The transfer saga began during Hapoel's first Conference League qualifier against Ludogorets, when Aveso was initially close to joining a Ukrainian club. However, complications arose due to the Ukrainian club's insistence on paying in cryptocurrency, which stalled and ultimately collapsed the deal. Hapoel then entered negotiations and finalized the transfer.
Medical examinations were a critical part of the process. After Aveso failed tests at Viktoria Plzen, he independently sought a second opinion from Bayern Munich's medical team, who cleared him as fit. Hapoel conducted their own thorough medical checks, including sending the player to Belgrade for additional tests and consulting Israeli medical experts, all confirming his fitness.
Aveso, who previously played alongside fellow Ghanaian Emmanuel Boateng and briefly with Louizo at Red Star, was encouraged by their positive endorsements of Hapoel. The club emphasized that Aveso, despite being only 20, has a winning mentality and exceptional skills. They also clarified that his arrival is not intended to replace Israeli player Stav Turiel but to complement him, with hopes that their partnership will strengthen the team.
This signing marks a significant investment and strategic move by Hapoel Tel Aviv to enhance their squad ahead of the upcoming season.
The same event, reported separately by each outlet. Open a few to compare what different newsrooms emphasize — and what they leave out.
Not the same event — other stories that share this one’s people, places, or theme: background, reactions, and follow-ups.